These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
    Author: Yamagishi H, Naito K, Maeda Y, Kobayashi M, Kurioka H, Fujimori C, Tanaka T, Hashimoto I.
    Journal: Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309.
    Abstract:
    The mechanism of anti-tumor effect of OK-432 was examined in C3H/He mice transplanted with methylcholanthrene induced fibrosarcomas. Tumor growth was significantly reduced in mice treated with OK-432 daily for 7 days after tumor inoculation. Tumor growth was significantly reduced in Sham-operated mice treated with OK-432 when compared to untreated controls. On the other hand, splenectomized mice failed to respond to OK-432 immunotherapy, suggesting the spleen is an essential organ in host responsiveness to this immunostimulant. Further dissection of the mechanism of OK-432 immunotherapy was achieved by Winn assay with spleen cells taken from mice inoculated with MCA-F (1 X 10(5) cells) and OK-432 for 7 days. Spleen cells from tumor-bearing mice which had been treated with OK-432 further reduced the tumor growth compared with spleen cells from tumor-bearer and such cytotoxic activity was reduced by the spleen cells with treatment of anti-Thy 1. 2 serum plus complement or by 700 rads irradiation before Winn assay, suggesting that OK-432 generated cytotoxic T cell population in vivo.
    [Abstract] [Full Text] [Related] [New Search]